-
Je něco špatně v tomto záznamu ?
Polygenic risk for immuno-metabolic markers and specific depressive symptoms: A multi-sample network analysis study
N. Kappelmann, D. Czamara, N. Rost, S. Moser, V. Schmoll, L. Trastulla, J. Stochl, S. Lucae, CHARGE inflammation working group, EB. Binder, GM. Khandaker, J. Arloth
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural
- MeSH
- antidepresiva terapeutické užití MeSH
- C-reaktivní protein analýza MeSH
- deprese * genetika MeSH
- depresivní porucha unipolární * farmakoterapie genetika MeSH
- lidé MeSH
- multifaktoriální dědičnost MeSH
- zánět farmakoterapie genetika MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- Research Support, N.I.H., Extramural MeSH
BACKGROUND: About every fourth patient with major depressive disorder (MDD) shows evidence of systemic inflammation. Previous studies have shown inflammation-depression associations of multiple serum inflammatory markers and multiple specific depressive symptoms. It remains unclear, however, if these associations extend to genetic/lifetime predisposition to higher inflammatory marker levels and what role metabolic factors such as Body Mass Index (BMI) play. It is also unclear whether inflammation-symptom associations reflect direct or indirect associations, which can be disentangled using network analysis. METHODS: This study examined associations of polygenic risk scores (PRSs) for immuno-metabolic markers (C-reactive protein [CRP], interleukin [IL]-6, IL-10, tumour necrosis factor [TNF]-α, BMI) with seven depressive symptoms in one general population sample, the UK Biobank study (n = 110,010), and two patient samples, the Munich Antidepressant Response Signature (MARS, n = 1058) and Sequenced Treatment Alternatives to Relieve Depression (STAR*D, n = 1143) studies. Network analysis was applied jointly for these samples using fused graphical least absolute shrinkage and selection operator (FGL) estimation as primary analysis and, individually, using unregularized model search estimation. Stability of results was assessed using bootstrapping and three consistency criteria were defined to appraise robustness and replicability of results across estimation methods, network bootstrapping, and samples. RESULTS: Network analysis results displayed to-be-expected PRS-PRS and symptom-symptom associations (termed edges), respectively, that were mostly positive. Using FGL estimation, results further suggested 28, 29, and six PRS-symptom edges in MARS, STAR*D, and UK Biobank samples, respectively. Unregularized model search estimation suggested three PRS-symptom edges in the UK Biobank sample. Applying our consistency criteria to these associations indicated that only the association of higher CRP PRS with greater changes in appetite fulfilled all three criteria. Four additional associations fulfilled at least two consistency criteria; specifically, higher CRP PRS was associated with greater fatigue and reduced anhedonia, higher TNF-α PRS was associated with greater fatigue, and higher BMI PRS with greater changes in appetite and anhedonia. Associations of the BMI PRS with anhedonia, however, showed an inconsistent valence across estimation methods. CONCLUSIONS: Genetic predisposition to higher systemic inflammatory markers are primarily associated with somatic/neurovegetative symptoms of depression such as changes in appetite and fatigue, consistent with previous studies based on circulating levels of inflammatory markers. We extend these findings by providing evidence that associations are direct (using network analysis) and extend to genetic predisposition to immuno-metabolic markers (using PRSs). Our findings can inform selection of patients with inflammation-related symptoms into clinical trials of immune-modulating drugs for MDD.
Cambridgeshire and Peterborough NHS Foundation Trust Cambridge United Kingdom
Department of Kinanthropology Charles University Prague Czech Republic
Department of Psychiatry University of Cambridge Cambridge United Kingdom
Department of Translational Research in Psychiatry Max Planck Institute of Psychiatry Munich Germany
Institute of Computational Biology Helmholtz Zentrum Munich Neuherberg Germany
International Max Planck Research School for Translational Psychiatry Munich Germany
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21018405
- 003
- CZ-PrNML
- 005
- 20210830100001.0
- 007
- ta
- 008
- 210728s2021 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.bbi.2021.03.024 $2 doi
- 035 __
- $a (PubMed)33794315
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Kappelmann, Nils $u Department of Translational Research in Psychiatry, Max-Planck-Institute of Psychiatry, Munich, Germany; International Max Planck Research School for Translational Psychiatry (IMPRS-TP), Munich, Germany. Electronic address: n.kappelmann@gmail.com
- 245 10
- $a Polygenic risk for immuno-metabolic markers and specific depressive symptoms: A multi-sample network analysis study / $c N. Kappelmann, D. Czamara, N. Rost, S. Moser, V. Schmoll, L. Trastulla, J. Stochl, S. Lucae, CHARGE inflammation working group, EB. Binder, GM. Khandaker, J. Arloth
- 520 9_
- $a BACKGROUND: About every fourth patient with major depressive disorder (MDD) shows evidence of systemic inflammation. Previous studies have shown inflammation-depression associations of multiple serum inflammatory markers and multiple specific depressive symptoms. It remains unclear, however, if these associations extend to genetic/lifetime predisposition to higher inflammatory marker levels and what role metabolic factors such as Body Mass Index (BMI) play. It is also unclear whether inflammation-symptom associations reflect direct or indirect associations, which can be disentangled using network analysis. METHODS: This study examined associations of polygenic risk scores (PRSs) for immuno-metabolic markers (C-reactive protein [CRP], interleukin [IL]-6, IL-10, tumour necrosis factor [TNF]-α, BMI) with seven depressive symptoms in one general population sample, the UK Biobank study (n = 110,010), and two patient samples, the Munich Antidepressant Response Signature (MARS, n = 1058) and Sequenced Treatment Alternatives to Relieve Depression (STAR*D, n = 1143) studies. Network analysis was applied jointly for these samples using fused graphical least absolute shrinkage and selection operator (FGL) estimation as primary analysis and, individually, using unregularized model search estimation. Stability of results was assessed using bootstrapping and three consistency criteria were defined to appraise robustness and replicability of results across estimation methods, network bootstrapping, and samples. RESULTS: Network analysis results displayed to-be-expected PRS-PRS and symptom-symptom associations (termed edges), respectively, that were mostly positive. Using FGL estimation, results further suggested 28, 29, and six PRS-symptom edges in MARS, STAR*D, and UK Biobank samples, respectively. Unregularized model search estimation suggested three PRS-symptom edges in the UK Biobank sample. Applying our consistency criteria to these associations indicated that only the association of higher CRP PRS with greater changes in appetite fulfilled all three criteria. Four additional associations fulfilled at least two consistency criteria; specifically, higher CRP PRS was associated with greater fatigue and reduced anhedonia, higher TNF-α PRS was associated with greater fatigue, and higher BMI PRS with greater changes in appetite and anhedonia. Associations of the BMI PRS with anhedonia, however, showed an inconsistent valence across estimation methods. CONCLUSIONS: Genetic predisposition to higher systemic inflammatory markers are primarily associated with somatic/neurovegetative symptoms of depression such as changes in appetite and fatigue, consistent with previous studies based on circulating levels of inflammatory markers. We extend these findings by providing evidence that associations are direct (using network analysis) and extend to genetic predisposition to immuno-metabolic markers (using PRSs). Our findings can inform selection of patients with inflammation-related symptoms into clinical trials of immune-modulating drugs for MDD.
- 650 _2
- $a antidepresiva $x terapeutické užití $7 D000928
- 650 _2
- $a C-reaktivní protein $x analýza $7 D002097
- 650 12
- $a deprese $x genetika $7 D003863
- 650 12
- $a depresivní porucha unipolární $x farmakoterapie $x genetika $7 D003865
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a zánět $x farmakoterapie $x genetika $7 D007249
- 650 _2
- $a multifaktoriální dědičnost $7 D020412
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a Research Support, N.I.H., Extramural $7 D052061
- 700 1_
- $a Czamara, Darina $u Department of Translational Research in Psychiatry, Max-Planck-Institute of Psychiatry, Munich, Germany
- 700 1_
- $a Rost, Nicolas $u Department of Translational Research in Psychiatry, Max-Planck-Institute of Psychiatry, Munich, Germany; International Max Planck Research School for Translational Psychiatry (IMPRS-TP), Munich, Germany
- 700 1_
- $a Moser, Sylvain $u Department of Translational Research in Psychiatry, Max-Planck-Institute of Psychiatry, Munich, Germany; International Max Planck Research School for Translational Psychiatry (IMPRS-TP), Munich, Germany
- 700 1_
- $a Schmoll, Vanessa $u Department of Translational Research in Psychiatry, Max-Planck-Institute of Psychiatry, Munich, Germany
- 700 1_
- $a Trastulla, Lucia $u Department of Translational Research in Psychiatry, Max-Planck-Institute of Psychiatry, Munich, Germany
- 700 1_
- $a Stochl, Jan $u Department of Psychiatry, University of Cambridge, Cambridge, United Kingdom; Department of Kinanthropology, Charles University, Prague, Czech Republic
- 700 1_
- $a Lucae, Susanne $u Max-Planck-Institute of Psychiatry, Munich, Germany
- 700 1_
- $a Binder, Elisabeth B $u Department of Translational Research in Psychiatry, Max-Planck-Institute of Psychiatry, Munich, Germany
- 700 1_
- $a Khandaker, Golam M $u Department of Psychiatry, University of Cambridge, Cambridge, United Kingdom; Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, United Kingdom; MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom; Centre for Academic Mental Health, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom
- 700 1_
- $a Arloth, Janine $u Department of Translational Research in Psychiatry, Max-Planck-Institute of Psychiatry, Munich, Germany; Institute of Computational Biology, Helmholtz Zentrum Munich, Neuherberg, Germany
- 710 2_
- $a CHARGE inflammation working group
- 773 0_
- $w MED00000839 $t Brain, behavior, and immunity $x 1090-2139 $g Roč. 95, č. - (2021), s. 256-268
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33794315 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20210830100001 $b ABA008
- 999 __
- $a ok $b bmc $g 1689503 $s 1138849
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 95 $c - $d 256-268 $e 20210329 $i 1090-2139 $m Brain, behavior, and immunity $n Brain Behav Immun $x MED00000839
- LZP __
- $a Pubmed-20210728